Scholarlink

Abstract <p>In recent years, cancer immunotherapy has become one of the most important methods in cancer treatment, which can kill tumors by activating the immune system. The PD-1/PD-L1 immune checkpoint signaling pathway in the tumor microenvironment can impair T cell responses and thereby promote tumor immune escape. Blocking the PD-1/PD-L1 signaling pathway can enhance the antitumor immune response and improve the therapeutic effect. Anti-PD-1/PD-L1 antibodies have shown antitumor effects in clinical practice and are revolutionizing the field of cancer management. Recent studies have shown that the PD-1/PD-L1 pathway in the tumor microenvironment is finely regulated, and inhibition of the PD-1/PD-L1 signal by targeting its regulatory mechanism can activate the antitumor immune response and reverse the tumor immunosuppressive microenvironment. New strategies and drugs designed and developed for the PD-1/PD-L1 blockade have brought new hope for better treatment of tumors.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strategies to target PD-1/PD-L1 in the tumor microenvironment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Yulan Kui,
  • Fan Tong,
  • Ruiguang Zhang,
  • Xiaorong Dong,
  • Jian Wang

摘要

Abstract

In recent years, cancer immunotherapy has become one of the most important methods in cancer treatment, which can kill tumors by activating the immune system. The PD-1/PD-L1 immune checkpoint signaling pathway in the tumor microenvironment can impair T cell responses and thereby promote tumor immune escape. Blocking the PD-1/PD-L1 signaling pathway can enhance the antitumor immune response and improve the therapeutic effect. Anti-PD-1/PD-L1 antibodies have shown antitumor effects in clinical practice and are revolutionizing the field of cancer management. Recent studies have shown that the PD-1/PD-L1 pathway in the tumor microenvironment is finely regulated, and inhibition of the PD-1/PD-L1 signal by targeting its regulatory mechanism can activate the antitumor immune response and reverse the tumor immunosuppressive microenvironment. New strategies and drugs designed and developed for the PD-1/PD-L1 blockade have brought new hope for better treatment of tumors.

Clinical trial number

Not applicable.